Dr. Rob Koremans to succeed Dr. Gerard van Odijk as President and CEO of Teva Europe
After six intensive years, Dr. Gerard van Odijk, Teva Europe’s current President and CEO has decided to step down.
In the next few months, Dr. Koremans and Dr. van Odijk will work closely together to ensure a smooth transition. Dr. van Odijk will remain with Teva to support the EU region for the remainder of 2012.
Shlomo Yanai, President and CEO of Teva Pharmaceutical Industries, said, “I would like to express my personal and profound thanks to Gerard van Odijk for his leadership of Teva in Europe. Under his management, our business in Europe has been transformed as Teva became the undisputed generics leader in this major and growing market and established a strong position in specialty pharmaceuticals. I respect Gerard's decision to step down and spend more time with his family, and I wish him a lot of success in the future. I am very confident that Rob Koremans, together with our strong European management, will continue our success story across Europe”.
Dr. Rob Koremans (49) holds a medical degree from Erasmus University of Rotterdam, Netherlands. He began his career in 1988 at Sanofi SA. In 1993 he joined the Serono Group and was appointed Vice-President, Europe in 1998; from 2007 to 2009, Rob was Chief Executive Officer of Cryo-Save, Europe’s leading Stem Cell Storage Company. He returned to Sanofi in 2009 as Senior Vice President, Generics Europe, Sanofi-Aventis, and CEO of Zentiva. He was appointed President of Zentiva in July 2010 and later became Sanofi’s Senior Vice President Generic Strategy and Development.